Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › CT-388-104 (T2D)

CT-388-104 (T2D)

CT-388 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CT-388
Population
t2d
Phase
2
Duration
48 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
enicepatide 24 mgt2d48———−15.5 %
estimand not specified
−2.6——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (1)
  • enicepatide 24 mg · weight_unsp · company announcement
    The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: CT-388-104 (T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-104/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.